Key statistics
On Thursday, Biohaven Ltd (BHVN:NYQ) closed at 28.22, 5.30% above its 52-week low of 26.80, set on May 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 29.25 |
---|---|
High | 29.73 |
Low | 27.94 |
Bid | 27.60 |
Offer | 29.97 |
Previous close | 29.41 |
Average volume | 1.62m |
---|---|
Shares outstanding | 101.12m |
Free float | 85.42m |
P/E (TTM) | -- |
Market cap | 3.89bn USD |
EPS (TTM) | -9.35 USD |
Data delayed at least 15 minutes, as of Mar 13 2025 20:10 BST.
More ▼
- Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
- Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
- Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
- Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy
- Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
More ▼